Most Clicked StoriesMore >


Report: Global drug sales may fall $65 billion by 2019

BIO SmartBrief | Dec 12, 2014

A GlobalData report predicts that global pharmaceutical sales will drop about $65 billion by 2019 as a result of the patent expiration of several major drugs. A large portion of sales losses are expected to come from the central nervous system therapy market. AstraZeneca, Eli Lilly and Otsuka are predicted to be most affected. BioSpectrum Asia (12/11) Chain Drug Review (12/11)


Drugs for unmet needs would get 15-year data exclusivity under Senate bill

BIO SmartBrief | Dec 16, 2014

Lilly drug gets FDA nod to treat lung cancer

BIO SmartBrief | Dec 15, 2014

Ebola vaccine makers offered legal immunity in U.S.

BIO SmartBrief | Dec 11, 2014

Merck's 9-valent HPV vaccine wins FDA approval

BIO SmartBrief | Dec 11, 2014

Bluebird bio's gene therapy shows promise against beta-thalassemia

BIO SmartBrief | Dec 11, 2014

Senate bill aims to boost access to new antibiotics

BIO SmartBrief | Dec 15, 2014

Prostate cancer drug developer gets $8M from investors

BIO SmartBrief | Dec 15, 2014

Pfizer licenses OPKO's GHD treatment in deal that could surpass $570M

BIO SmartBrief | Dec 16, 2014

Reaction to Ebola crisis could improve drug R&D

BIO SmartBrief | Dec 11, 2014


Find BIO SmartBrief Issues by Date:



BIO News More >


Industrial biotechnology with a French twist!

BIO SmartBrief | Dec 17, 2014

Registration is open for the BIO CEO & Investor Conference!

BIO SmartBrief | Dec 16, 2014

Fall 2014 BIO Therapeutic Newsletters

BIO SmartBrief | Dec 15, 2014

Faster & better connections with quality R&D vendors

BIO SmartBrief | Dec 11, 2014

New BIO Survey Tool: FDA/Sponsor Interactions During Drug Development

BIO SmartBrief | Dec 08, 2014




Sign up for BIO SmartBrief



Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more